Clinical Trials

The James Cancer Center Columbus, OH

open for enrollment

Ph III, Nivolumab w/Ipilimumab vs SOC Chemotherapy w/ Untreated/ Unresectable or Metastatic Urothe

Protocol: OSU-17139

Full Title

A Phase III, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer.

Genitourinary Cancers Bladder Cancer